Optimizing detection of Alzheimer's disease in mild cognitive impairment: a 4-year biomarker study of mild behavioral impairment in ADNI and MEMENTO.
Zahinoor IsmailRebeca LeonByron CreeseClive BallardPhilippe RobertEric E SmithPublished in: Molecular neurodegeneration (2023)
These findings support a biological basis for NPS that meet MBI criteria, the continued inclusion of MBI in NIA-AA ATN clinical staging, and the utility of MBI criteria to improve identification of patients for enrollment in disease-modifying drug trials or for clinical care.
Keyphrases
- mild cognitive impairment
- cognitive decline
- end stage renal disease
- newly diagnosed
- healthcare
- ejection fraction
- chronic kidney disease
- lymph node
- palliative care
- prognostic factors
- quality improvement
- health insurance
- affordable care act
- patient reported outcomes
- pet ct
- pain management
- loop mediated isothermal amplification